Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 4, 2024

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2027

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Envafolimab and recombinant human endostatin combined with chemoradiotherapy

Induction treatment phase: Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 8 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7 weeks,5 fractions/week, 1 fraction/day.

Trial Locations (1)

400030

RECRUITING

Chongqing University Cancer Hospital, Chongqing

All Listed Sponsors
collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

Sun Yat-sen University

OTHER

lead

Chongqing University Cancer Hospital

OTHER